Mikhail N. Kosiborod, MD, Professor of Medicine, Director of Cardiometabolic Research and Co-Director of the Saint Luke’s Michael & Marlys Haverty Cardiometabolic Center of Excellence. In this video, he speaks about A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure (EMPULSE).
This is a study of adults admitted to the hospital with acute heart failure. The goal of this trial is to see if beginning a drug called empagliflozin immediately after being admitted to the hospital helps persons with acute heart failure.
Participants will be enrolled in the trial for approximately three months. Participants are still in the hospital at the start. Later, they visit the hospital three times and receive one phone call. Participants are randomly assigned to one of two groups. One group receives one empagliflozin pill every day. The other group chooses
One placebo tablet per day. Placebo tablets resemble empagliflozin tablets but contain no medication. Empagliflozin is an SGLT-2 inhibitor, which is a type of medication. It is employed in the treatment of type 2 diabetes.
During the trial, doctors look to see if participants have any more heart failure events, such as needing to go to the hospital again due to heart failure. Participants respond to questions regarding how their heart failure affects their daily lives. The outcomes are then compared between the empagliflozin and placebo groups. The participants' overall health is also checked on a regular basis by the doctors.